Nolato AB (publ) (NOLA_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to today's presentation with Nolato, where CEO Casey Wahlquist and CFO Paolo Holmström will present a report for the first quarter of 2026. After the presentation, there will be a Q&A. So if you're calling in and want to ask a question, please press star nine to raise your hand, and then star six to unmute yourself when handed the word. You can also send in questions via the form to the right. And with that said, I hand over the word to you guys. Thank you, and welcome to the presentation of Nolato's first quarter of 2026. Chris DeWalker speaking here and starting on page two. The first quarter, during the first quarter of 2026, we saw growth in both our business areas, despite a very volatile geopolitical situation. The total organic growth, if we adjust for currency, ended up at 3%. And it was a little bit stronger on the medical side with 5% and 1% on the engineer side. That summarizes to an EBIT A of 260. And of course, the EBIT A was strongly affected by currency headwinds as we calculated 7%. We kept our margins on 11% and sustaining them in a good way. And, of course, our strong financial position with very good possibilities to execute our acquisition agenda remains. Turning to page three, summarizing the Nolato group, the group consists of two business areas, the medical solution at 57% of the total and the engineered solution at 43%. Of course, it's two different markets, but behind the scenes, we are doing similar things, of course, with some different growth drivers and the different key needed things. But the two business areas create synergies by combining them to the customer interface. Then we jump to page four, summarizing the first of the medical solutions. And here we can see a 20-year graph of our development. And we are, of cou...